Ribociclib has been extensively studied in clinical trials. The MONALEESA series of trials (MONALEESA-2, MONALEESA-3, and MONALEESA-7) have demonstrated its efficacy and safety in various patient populations with HR+, HER2- advanced breast cancer. These studies have shown that ribociclib, in combination with endocrine therapy, significantly improves progression-free survival compared to endocrine therapy alone.
